

PATENT
ATTORNEY DOCKET NO. 50291/016003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christer Nordstedt et al. Confirmation No.: 6338
Serial No: 10/721,774 Art Unit: 1631
Filed: November 26, 2003 Examiner: Michael L. Borin
Customer No.: 21559
Title: Peptide Binding the KLVFF-Sequence of Amyloid-Beta

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Applicants note that the Examiner stated in a telephone interview on June 11, 2007 that he would review this submission, despite it being submitted after the receipt of a Notice of Allowance. Applicants respectfully request that an initialed copy of the enclosed Form PTO 1449 be returned to their representative as soon as possible, prior to

the issue fee payment deadline.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: July 26, 2007

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	4,116,768	Sep. 26, 1978	Isowa et al.
	5,002,872	Mar. 26, 1991	Gross
	5,470,951	Nov. 28, 1995	Roberts
	5,514,548	May 7, 1996	Krebber et al.
	5,652,334	Jul. 29, 1997	Roberts
	5,688,651	Nov. 18, 1997	Soloman
	5,721,130	Feb. 24, 1998	Seubert et al.
	5,817,626	Oct. 6, 1998	Findeis et al.
	5,837,672	Nov. 17, 1998	Schenk et al.
	5,854,215	Dec. 29, 1998	Findeis et al.
	5,869,093	Feb. 9, 1999	Weiner and Hafler
	5,891,991	Apr. 6, 1999	Wasco et al.
	6,022,859	Feb. 8, 2000	Kiessling and Murphy
	6,261,569	Jul. 17, 2001	Comis et al.
	6,277,826	Aug. 21, 2001	Findeis et al.
	6,319,498	Nov. 20, 2001	Findeis et al.
	6,331,440	Dec. 18, 2001	Nordstedt et al.
	6,436,903	Aug. 20, 2002	Clayberger and Krensky
	6,610,658	Aug. 26, 2003	Findeis et al.
	6,670,399	Dec. 30, 2003	Green and Gervais
	6,689,752	Feb. 10, 2004	Findeis et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
	6,710,226	Mar. 23, 2004	Schenk
	6,743,427	Jun. 1, 2004	Schenk
	6,750,324	Jun. 15, 2004	Schenk et al.
	6,761,888	Jul. 13, 2004	Schenk et al.
	6,787,138	Sep. 7, 2004	Schenk
	6,787,139	Sep. 7, 2004	Schenk
	6,787,140	Sep. 7, 2004	Schenk
	6,787,143	Sep. 7, 2004	Schenk
	6,787,144	Sep. 7, 2004	Schenk
	6,787,523	Sep. 7, 2004	Schenk
	6,787,637	Sep. 7, 2004	Schenk
	6,808,712	Oct. 26, 2004	Schenk
	6,818,218	Nov. 16, 2004	Schenk
	6,831,066	Dec. 14, 2004	Findeis and Phillips
	6,866,849	Mar. 15, 2005	Schenk
	6,866,850	Mar. 15, 2005	Schenk
	6,875,434	Apr. 5, 2005	Schenk
	7,060,670	Jun. 13, 2006	Chalifour et al.
	20040157781	Aug. 12, 2004	Nordstedt et al.
	20050090439	Apr. 28, 2005	Chalifour et al.
	20060199771	Sep. 7, 2006	Chalifour et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	AU 199870091	Jul. 30, 1998	A.P.O.	
	EP 0584452 A1	Mar. 2, 1994	E.P.O.	
	EP 0584452 B1	Jul. 31, 2002	E.P.O.	
	EP 0752886 B1	Jan. 28, 1998	E.P.O.	
	WO 94/05311	Mar. 17, 1994	W.I.P.O.	
	WO 94/14836	Jul. 7, 1994	W.I.P.O.	
	WO 94/19692	Sep. 1, 1994	W.I.P.O.	
	WO 95/05393	Feb. 23, 1995	W.I.P.O.	
	WO 95/05849	Mar. 2, 1995	W.I.P.O.	
	WO 95/08999	Apr. 6, 1995	W.I.P.O.	
	WO 95/12815	May 11, 1995	W.I.P.O.	
	WO 95/23166	Aug. 31, 1995	W.I.P.O.	
	WO 95/31966	Nov. 30, 1995	W.I.P.O.	
	WO 96/13583	May 9, 1996	W.I.P.O.	
	WO 96/28471	Sep. 19, 1996	W.I.P.O.	
	WO 96/34887	Nov. 7, 1996	W.I.P.O.	
	WO 96/37621	Nov. 28, 1996	W.I.P.O.	
	WO 97/08320	Mar. 6, 1997	W.I.P.O.	
	WO 97/21728	Jun. 19, 1997	W.I.P.O.	
	WO 97/32017	Sep. 4, 1997	W.I.P.O.	
	WO 98/02462	Jan. 22, 1998	W.I.P.O.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO 98/05350	Feb. 12, 1998	W.I.P.O.
	WO 98/08868	Mar. 5, 1998	W.I.P.O.
	WO 98/22120	May 28, 1998	W.I.P.O.
	WO 99/06587	Feb. 11, 1999	W.I.P.O.
	WO 99/27944	Jun. 10, 1999	W.I.P.O.
	WO 99/27949	Jun. 10, 1999	W.I.P.O.
	WO 99/58564	Nov. 18, 1999	W.I.P.O.
	WO 99/60021	Nov. 25, 1999	W.I.P.O.
	WO 99/60024	Nov. 25, 1999	W.I.P.O.
	WO 00/20027	Apr. 13, 2000	W.I.P.O.
	WO 00/26238	May 11, 2000	W.I.P.O.
	WO 00/43039	Jul. 27, 2000	W.I.P.O.
	WO 00/52048	Sep. 8, 2000	W.I.P.O.
	WO 00/68263	Nov. 16, 2000	W.I.P.O.
	WO 00/72880	Dec. 7, 2000	W.I.P.O.
	WO 01/39796	Jun. 7, 2001	W.I.P.O.

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Alberts, "Molecular Biology of the Cell," Garland Publishing, pg. 54, 1989.
	Bard et al., "Peripherally Administered Antibodies Against Amyloid β -Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," <i>Nature Med.</i> 6(8):916-919, 2000.
	Benkirane et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> 268(35):26279-26285, 1993.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Chen et al., "Neurodegenerative Alzheimer-Like Pathology in PDAPP 717V->F Transgenic Mice," <i>Prog. Brain Res.</i> 117:327-334, 1998.
	Cribbs et al., "All-D-Enantiomers of β -Amyloid Exhibit Similar Biological Properties to All-L- β -Amyloids," <i>J. Biol. Chem.</i> 272(11):7431-7436, 1997.
	DeMattos et al., "Peripheral Anti-A β Antibody Alters CNS and Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <i>Proc. Nat. Acad. Sci. U.S.A.</i> 98(15):8850-8855, 2001.
	Findeis et al., "Modified-Peptide Inhibitors of Amyloid β -Peptide Polymerization," <i>Biochemistry</i> 38(21):6791-6800, 1999.
	Flood et al., "Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-Activity Studies: Relation to Amnestic Effect of Amyloid β Protein," <i>Proc. Nat. Acad. Sci. U.S.A.</i> 91:380-384, 1994.
	Frenkel, "Generation of Auto-Antibodies Towards Alzheimer's Disease Vaccination," <i>Vaccine</i> 19(17-19):2615-2619, 2001.
	Frenkel et al., "Immunization Against Alzheimer's β -Amyloid Plaques Via EFRH Phage Administration," <i>Proc. Nat. Acad. Sci. U.S.A.</i> 97(21):11455-11459, 2000.
	Games et al., "Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein," <i>Nature</i> 373(6514):523-527, 1995.
	Giulian et al., "The HHQK Domain of β -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>J. Biol. Chem.</i> 273(45):29719-29726, 1998.
	Janus et al., "A β Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," <i>Nature</i> 408(6815):979-982, 2000.
	Jobling and Holmes, "Analysis of Structure and Function of the B Subunit of Cholera Toxin by the Use of Site-Directed Mutagenesis," <i>Mol. Microbiol.</i> 5(7):1755-1767, 1991.
	Kalaria, "The Blood-Brain Barrier and Cerebrovascular Pathology in Alzheimer's Disease," <i>Ann. N.Y. Acad. Sci.</i> 893:113-125, 1999.
	Lemere et al., Society for Neuroscience Abstracts, Vol. 25, part 1, Abstract 519.6, 29th Annual Meeting 10/23-10/28, 1999.
	Morgan et al., "A β Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," <i>Nature</i> 408(6815):982-985, 2000.
	Münch and Robinson, "Potential Neurotoxic Inflammatory Responses to A β Vaccination in Humans," <i>J. Neural Transmiss.</i> 109(7-8):1081-1087, 2002.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50291/016003 10/721,774 Nordstedt et al. November 26, 2003 1631 July 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Pike et al., "Neurodegeneration Induced by β -Amyloid Peptides <i>in vitro</i> : the Role of Peptide Assembly State," <i>J. Neurosci.</i> 13(4):1676-1687, 1993.
	Schenk et al., "Immunization with Amyloid- β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse," <i>Nature</i> 400(6740):173-177, 1999.
	Sela and Zisman, "Different Roles of D-Amino Acids in Immune Phenomena," <i>FASEB J.</i> 11(6):449-456, 1997.
	Skolnick and Fetrow, "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," <i>Trends Biotech.</i> 18(1):34-39, 2000.
	Soto et al., "Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent β -Sheet Conformation," <i>Biochem. Biophys. Res. Comm.</i> 226(3):672-680, 1996.
	Thompson et al., "Vanadium Compounds as Insulin Mimics," <i>Chem. Rev.</i> 99(19):2561-2571, 1999.
	Tjernberg et al., "Controlling Amyloid β -Peptide Fibril Formation with Protease-Stable Ligands," <i>J. Biol. Chem.</i> 272(19):12601-12605, 1997.
	Tjernberg et al., "Controlling Amyloid β -Peptide Fibril Formation with Protease-Stable Ligands," <i>J. Biol. Chem.</i> 272(28):17894, 1997.
	Torneiro and Still, "Sequence-Selective Binding of Peptides in Water by a Synthetic Receptor Molecule," <i>J. Am. Chem. Soc.</i> 117:5887-5888, 1995.
	Van Regenmortel and Muller, "D-Peptides as Immunogens and Diagnostic Reagents," <i>Curr. Opin. Biotech.</i> 9(4):377-382, 1998.
	Wehner et al., "Cytoprotective Function of sAPP α in Human Keratinocytes," <i>Eur. J. Cell. Biol.</i> 83(11-12):701-708, 2004.
	Wong et al., "Absence of Protease-Resistant Prion Protein in the Cerebrospinal Fluid of Creutzfeldt-Jakob Disease," <i>J. Pathol.</i> 194(1):9-14, 2001.
	Younkin, "Amyloid β Vaccination: Reduced Plaques and Improved Cognition," <i>Nature Med.</i> 7(1):18-19, 2001.
	International Search Report for PCT/CA00/00515 dated December 5, 2000.
	International Preliminary Report on Patentability from PCT/CA00/00515 dated August 10, 2001.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	